Pub Date : 2024-11-14DOI: 10.1182/blood.2024025679
Xavier Deschênes-Simard, Bianca D Santomasso, Parastoo B Dahi
Abstract: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies, but it comes with unique toxicities, notably cytokine release syndrome and ICANS (immune effector cell-associated neurotoxicity syndrome). As experience with CAR T-cell therapy grows, distinct and infrequent neurologic complications are becoming increasingly evident. Recently, reports of acute myelopathy after the administration of CAR T-cell therapies have been accumulating. Despite the establishment of consensus guidelines for managing ICANS, there remains limited guidance on the appropriate investigations and treatments for this rare complication. In this manuscript, we delve into the clinical features, pathophysiology, and strategies for the optimal management of acute myelitis after CAR T-cell therapy and draw insights from reported cases in the literature.
嵌合抗原受体(CAR)T 细胞疗法为复发或难治性血液恶性肿瘤患者的治疗带来了革命性的变化,但它也有独特的毒性,尤其是细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)。随着 CAR T 细胞疗法经验的增加,独特且不常见的神经系统并发症也越来越明显。最近,有关使用 CAR T 细胞疗法后出现急性脊髓病的报道不断增加。尽管已制定了管理 ICANS 的共识指南,但关于这一罕见并发症的适当检查和治疗的指导仍然有限。在此,我们将从文献报道的病例中汲取灵感,深入探讨CAR T细胞疗法后急性脊髓炎的临床特征、病理生理学和最佳治疗策略。
{"title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.","authors":"Xavier Deschênes-Simard, Bianca D Santomasso, Parastoo B Dahi","doi":"10.1182/blood.2024025679","DOIUrl":"10.1182/blood.2024025679","url":null,"abstract":"<p><strong>Abstract: </strong>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies, but it comes with unique toxicities, notably cytokine release syndrome and ICANS (immune effector cell-associated neurotoxicity syndrome). As experience with CAR T-cell therapy grows, distinct and infrequent neurologic complications are becoming increasingly evident. Recently, reports of acute myelopathy after the administration of CAR T-cell therapies have been accumulating. Despite the establishment of consensus guidelines for managing ICANS, there remains limited guidance on the appropriate investigations and treatments for this rare complication. In this manuscript, we delve into the clinical features, pathophysiology, and strategies for the optimal management of acute myelitis after CAR T-cell therapy and draw insights from reported cases in the literature.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":"2083-2094"},"PeriodicalIF":21.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kohta Kasai, Takashi Nojima, Yu Wang, Tao Xu, Hiroyuki Hirakata, Takahiro Shimada
Exploring complex topological structures in condensed matter has shown promising applications in nanotechnology. Although polar topologies such as chiral vortices and skyrmions have been observed in ferroelectric heterostructures, their existence in simple systems has posed challenges due to the absence of intrinsic noncollinear interaction (like Dzyaloshinskii-Moriya interaction in ferromagnetics). Here, we demonstrate that a nanoindentation mechanically switches local polarizations to stable polar topologies, including skyrmions, within a room-temperature PbTiO3 thin film via the flexoelectric effect as a noncollinear (Dzyaloshinskii-Moriya-like) driving force using phase-field simulations. In addition, by moving the indenter, the continuous polarization switching leads to the "writing" of arbitrary polar patterns (such as donut-like skyrmionium). Furthermore, the written topologies can be "erased" by applying a voltage with the same conducted indenter. Therefore, this study shows the writing and erasing process of room-temperature polar topologies in a ferroelectric thin film, which significantly advances their potential applications.
{"title":"Mechanical Writing of Polar Skyrmionic Topological States via Extrinsic Dzyaloshinskii-Moriya-like Flexoelectricity in Ferroelectric Thin Films.","authors":"Kohta Kasai, Takashi Nojima, Yu Wang, Tao Xu, Hiroyuki Hirakata, Takahiro Shimada","doi":"10.1021/acsnano.4c06137","DOIUrl":"10.1021/acsnano.4c06137","url":null,"abstract":"<p><p>Exploring complex topological structures in condensed matter has shown promising applications in nanotechnology. Although polar topologies such as chiral vortices and skyrmions have been observed in ferroelectric heterostructures, their existence in simple systems has posed challenges due to the absence of intrinsic noncollinear interaction (like Dzyaloshinskii-Moriya interaction in ferromagnetics). Here, we demonstrate that a nanoindentation mechanically switches local polarizations to stable polar topologies, including skyrmions, within a room-temperature PbTiO<sub>3</sub> thin film via the flexoelectric effect as a noncollinear (Dzyaloshinskii-Moriya-like) driving force using phase-field simulations. In addition, by moving the indenter, the continuous polarization switching leads to the \"writing\" of arbitrary polar patterns (such as donut-like skyrmionium). Furthermore, the written topologies can be \"erased\" by applying a voltage with the same conducted indenter. Therefore, this study shows the writing and erasing process of room-temperature polar topologies in a ferroelectric thin film, which significantly advances their potential applications.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14DOI: 10.1182/blood.2024024590
Mara John, Moutaz Helal, Johannes Duell, Greta Mattavelli, Emilia Stanojkovska, Nazia Afrin, Alexander M Leipold, Maximilian J Steinhardt, Xiang Zhou, David Žihala, Anjana Anilkumar Sithara, Julia Mersi, Johannes M Waldschmidt, Christine Riedhammer, Sofie-Katrin Kadel, Marietta Truger, Rudolf A Werner, Claudia Haferlach, Hermann Einsele, Kai Kretzschmar, Tomáš Jelínek, Andreas Rosenwald, K Martin Kortüm, Angela Riedel, Leo Rasche
Abstract: Extramedullary disease (EMD) is a high-risk feature of multiple myeloma (MM) and remains a poor prognostic factor, even in the era of novel immunotherapies. Here, we applied spatial transcriptomics (RNA tomography for spatially resolved transcriptomics [tomo-seq] [n = 2] and 10x Visium [n = 12]) and single-cell RNA sequencing (n = 3) to a set of 14 EMD biopsies to dissect the 3-dimensional architecture of tumor cells and their microenvironment. Overall, infiltrating immune and stromal cells showed both intrapatient and interpatient variations, with no uniform distribution over the lesion. We observed substantial heterogeneity at the copy number level within plasma cells, including the emergence of new subclones in circumscribed areas of the tumor, which is consistent with genomic instability. We further identified the spatial expression differences between GPRC5D and TNFRSF17, 2 important antigens for bispecific antibody therapy. EMD masses were infiltrated by various immune cells, including T cells. Notably, exhausted TIM3+/PD-1+ T cells diffusely colocalized with MM cells, whereas functional and activated CD8+ T cells showed a focal infiltration pattern along with M1 macrophages in tumor-free regions. This segregation of fit and exhausted T cells was resolved in the case of response to T-cell-engaging bispecific antibodies. MM and microenvironment cells were embedded in a complex network that influenced immune activation and angiogenesis, and oxidative phosphorylation represented the major metabolic program within EMD lesions. In summary, spatial transcriptomics has revealed a multicellular ecosystem in EMD with checkpoint inhibition and dual targeting as potential new therapeutic avenues.
{"title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma.","authors":"Mara John, Moutaz Helal, Johannes Duell, Greta Mattavelli, Emilia Stanojkovska, Nazia Afrin, Alexander M Leipold, Maximilian J Steinhardt, Xiang Zhou, David Žihala, Anjana Anilkumar Sithara, Julia Mersi, Johannes M Waldschmidt, Christine Riedhammer, Sofie-Katrin Kadel, Marietta Truger, Rudolf A Werner, Claudia Haferlach, Hermann Einsele, Kai Kretzschmar, Tomáš Jelínek, Andreas Rosenwald, K Martin Kortüm, Angela Riedel, Leo Rasche","doi":"10.1182/blood.2024024590","DOIUrl":"10.1182/blood.2024024590","url":null,"abstract":"<p><strong>Abstract: </strong>Extramedullary disease (EMD) is a high-risk feature of multiple myeloma (MM) and remains a poor prognostic factor, even in the era of novel immunotherapies. Here, we applied spatial transcriptomics (RNA tomography for spatially resolved transcriptomics [tomo-seq] [n = 2] and 10x Visium [n = 12]) and single-cell RNA sequencing (n = 3) to a set of 14 EMD biopsies to dissect the 3-dimensional architecture of tumor cells and their microenvironment. Overall, infiltrating immune and stromal cells showed both intrapatient and interpatient variations, with no uniform distribution over the lesion. We observed substantial heterogeneity at the copy number level within plasma cells, including the emergence of new subclones in circumscribed areas of the tumor, which is consistent with genomic instability. We further identified the spatial expression differences between GPRC5D and TNFRSF17, 2 important antigens for bispecific antibody therapy. EMD masses were infiltrated by various immune cells, including T cells. Notably, exhausted TIM3+/PD-1+ T cells diffusely colocalized with MM cells, whereas functional and activated CD8+ T cells showed a focal infiltration pattern along with M1 macrophages in tumor-free regions. This segregation of fit and exhausted T cells was resolved in the case of response to T-cell-engaging bispecific antibodies. MM and microenvironment cells were embedded in a complex network that influenced immune activation and angiogenesis, and oxidative phosphorylation represented the major metabolic program within EMD lesions. In summary, spatial transcriptomics has revealed a multicellular ecosystem in EMD with checkpoint inhibition and dual targeting as potential new therapeutic avenues.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":"2121-2135"},"PeriodicalIF":21.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14DOI: 10.1182/blood.2024024187
Rebecca L Zon, Aswin Sekar, Katharine Clapham, Ohad Oren, Abhishek Niroula, Alexander G Bick, Christopher J Gibson, Gabriel Griffin, Md Mesbah Uddin, Donna Neuberg, Pradeep Natarajan, Benjamin L Ebert
Abstract: Venous thromboembolism (VTE) is common among older individuals, but provoking factors are not identified in many cases. Patients with myeloid malignancies, especially myeloproliferative neoplasms (MPNs), are at increased risk for venous thrombosis. Clonal hematopoiesis of indeterminate potential (CHIP), a precursor state to myeloid malignancies, is common among older individuals and may similarly predispose to venous thrombosis. We evaluated overall and genotype-specific associations between CHIP and prevalent and incident VTE in >400 000 samples from the UK Biobank. CHIP was modestly associated with incident VTE with a hazard ratio (HR) of 1.17 (95% confidence interval [CI], 1.09-1.3; P = .002) but was not significantly associated with prevalent VTE with an odds ratio (OR) of 1.02 (95% CI, 0.81-1.23; P = .81). TET2-mutant CHIP was associated with incident VTE with a HR of 1.33 (95% CI, 1.05-1.69; P = .02). JAK2 mutations were highly associated with both prevalent and incident VTE risk, with an OR of 6.58 (95% CI, 2.65-16.29; P = 4.7 × 10-5) and a HR of 4.2 (95% CI, 2.18-8.08; P = 1.7 × 10-5), respectively, consistent with the thrombophilia associated with JAK2-mutant MPN. The association between JAK2-mutant CHIP and VTE remained significant after excluding potential undiagnosed MPN based on laboratory parameters. JAK2-mutant CHIP was more strongly associated with VTE but was less common than heterozygous factor V Leiden and heterozygous prothrombin gene mutation. These results indicate that most individuals with CHIP do not have an altered risk of thrombosis, but individuals with JAK2-mutant CHIP have a significantly elevated risk of VTE.
静脉血栓栓塞症(VTE)在老年人中很常见,但许多病例中的诱发因素并不明确。骨髓恶性肿瘤患者,尤其是骨髓增生性肿瘤患者,静脉血栓形成的风险更高。具有不确定潜能的克隆性造血(CHIP)是髓系恶性肿瘤的一种前体状态,在老年人中很常见,可能同样容易导致静脉血栓。我们评估了英国生物库中超过 40 万份样本中 CHIP 与流行性和偶发性 VTE 之间的总体关系和基因型特异性关系。CHIP与发生VTE的危险比为1.17(95%置信区间(CI)1.09-1.3;p= 0.002),关系不大,但与VTE流行的几率比为1.02(95% CI 0.81-1.23;p= 0.81)。TET2突变的CHIP与发生VTE相关,危险比为1.33 (95% CI 1.05-1.69; p=0.02)。JAK2突变与VTE的流行和发病风险高度相关,其几率比分别为6.58 (95% CI 2.65-16.29; p= 4.7 x 10-5)和4.2 (95% CI 2.18-8.08; p= 1.7 x 10-5),这与JAK2突变骨髓增殖性肿瘤相关的血栓性疾病一致。根据实验室参数排除潜在的未确诊骨髓增殖性肿瘤后,JAK2突变型CHIP与VTE之间的关联仍然显著。与杂合子因子V Leiden和杂合子凝血酶原基因突变相比,JAK2突变型CHIP与VTE的相关性更强,但并不常见。这些结果表明,大多数CHIP患者的血栓形成风险并没有改变,但JAK2突变型CHIP患者的VTE风险显著升高。
{"title":"JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism.","authors":"Rebecca L Zon, Aswin Sekar, Katharine Clapham, Ohad Oren, Abhishek Niroula, Alexander G Bick, Christopher J Gibson, Gabriel Griffin, Md Mesbah Uddin, Donna Neuberg, Pradeep Natarajan, Benjamin L Ebert","doi":"10.1182/blood.2024024187","DOIUrl":"10.1182/blood.2024024187","url":null,"abstract":"<p><strong>Abstract: </strong>Venous thromboembolism (VTE) is common among older individuals, but provoking factors are not identified in many cases. Patients with myeloid malignancies, especially myeloproliferative neoplasms (MPNs), are at increased risk for venous thrombosis. Clonal hematopoiesis of indeterminate potential (CHIP), a precursor state to myeloid malignancies, is common among older individuals and may similarly predispose to venous thrombosis. We evaluated overall and genotype-specific associations between CHIP and prevalent and incident VTE in >400 000 samples from the UK Biobank. CHIP was modestly associated with incident VTE with a hazard ratio (HR) of 1.17 (95% confidence interval [CI], 1.09-1.3; P = .002) but was not significantly associated with prevalent VTE with an odds ratio (OR) of 1.02 (95% CI, 0.81-1.23; P = .81). TET2-mutant CHIP was associated with incident VTE with a HR of 1.33 (95% CI, 1.05-1.69; P = .02). JAK2 mutations were highly associated with both prevalent and incident VTE risk, with an OR of 6.58 (95% CI, 2.65-16.29; P = 4.7 × 10-5) and a HR of 4.2 (95% CI, 2.18-8.08; P = 1.7 × 10-5), respectively, consistent with the thrombophilia associated with JAK2-mutant MPN. The association between JAK2-mutant CHIP and VTE remained significant after excluding potential undiagnosed MPN based on laboratory parameters. JAK2-mutant CHIP was more strongly associated with VTE but was less common than heterozygous factor V Leiden and heterozygous prothrombin gene mutation. These results indicate that most individuals with CHIP do not have an altered risk of thrombosis, but individuals with JAK2-mutant CHIP have a significantly elevated risk of VTE.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":"2149-2154"},"PeriodicalIF":21.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ferroptosis can induce cell death that leverages Fe2+-triggered Fenton reactions within living organisms, leading to an excessive accumulation of lipid peroxides (LPOs) and inducing cell death. Ferroptosis can effectively circumvent the inevitable drug resistance encountered with traditional apoptotic therapies. However, several issues remain in the clinical application of ferroptosis anticancer therapy, primarily due to the poor efficiency of intracellular Fenton reaction. To address this issue, we developed a supramolecular self-assembled codelivery nanoprodrug (DOX@C18Fc-Q[7] NPs) composed of ferrocene (Fc)-based supramolecular amphiphiles (C18Fc-Q[7]) and a nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) activator (doxorubicin, DOX). The C18Fc-Q[7] is based on Fc linked to a hydrophobic long-chain alkane via a disulfide linkage, which interacts with hydrophilic Q[7] to form self-assembled amphiphiles. Importantly, the host-guest interaction between Q[7] and Fc effectively enhances the solubility of Fc while maintaining the stability of the Fe2+ source. Moreover, C18Fc-Q[7] also acts as a good carrier for loading DOX due to its good self-assembly. In cancer cells, elevated glutathione (GSH) triggers the disassembly of nanoprodrug, leading to the release of DOX, which upregulates NOX4 expression and increases H2O2 level, thereby promoting an efficient Fenton reaction for Fc-induced ferroptosis. Moreover, DOX induces cell death through apoptosis, providing a synergistic effect to further enhance the ferroptosis therapy. In vivo studies have demonstrated that this enhanced ferroptosis therapy effectively inhibits tumor growth and metastasis while maintaining good biosafety.
铁凋亡可利用生物体内由 Fe2+ 触发的芬顿反应诱导细胞死亡,导致脂质过氧化物(LPO)过度积累并诱导细胞死亡。铁凋亡可有效规避传统凋亡疗法不可避免的耐药性问题。然而,铁氧体抗癌疗法在临床应用中仍存在一些问题,主要是由于细胞内芬顿反应的效率较低。为了解决这个问题,我们开发了一种超分子自组装编码递送纳米药物(DOX@C18Fc-Q[7] NPs),由二茂铁(Fc)基超分子双亲化合物(C18Fc-Q[7])和烟酰胺腺嘌呤二核苷酸磷酸氧化酶 4(NOX4)激活剂(多柔比星,DOX)组成。C18Fc-Q[7] 的基础是 Fc 通过二硫键与疏水性长链烷烃连接,后者与亲水性 Q[7] 相互作用,形成自组装的两亲化合物。重要的是,Q[7]和 Fc 之间的主客相互作用有效地提高了 Fc 的溶解度,同时保持了 Fe2+ 源的稳定性。此外,C18Fc-Q[7]还因其良好的自组装性而成为装载 DOX 的良好载体。在癌细胞中,谷胱甘肽(GSH)的升高会引发纳米药物的解体,导致 DOX 的释放,而 DOX 会上调 NOX4 的表达并增加 H2O2 的水平,从而促进 Fc 诱导的铁凋亡的高效芬顿反应。此外,DOX 还能通过细胞凋亡诱导细胞死亡,从而产生协同效应,进一步提高铁中毒疗法的效果。体内研究表明,这种增强型铁氧化疗法能有效抑制肿瘤生长和转移,同时保持良好的生物安全性。
{"title":"A Supramolecular Self-Assembled Nanoprodrug for Enhanced Ferroptosis Therapy.","authors":"Zhengwei Yu, Xin Xie, Qing Li, Yong Huang, Siqin Chen, Wentao Song, Jianwu Tian, Zhiyao Li, Chongzhi Wu, Bowen Li","doi":"10.1021/acsnano.4c09254","DOIUrl":"https://doi.org/10.1021/acsnano.4c09254","url":null,"abstract":"<p><p>Ferroptosis can induce cell death that leverages Fe<sup>2+</sup>-triggered Fenton reactions within living organisms, leading to an excessive accumulation of lipid peroxides (LPOs) and inducing cell death. Ferroptosis can effectively circumvent the inevitable drug resistance encountered with traditional apoptotic therapies. However, several issues remain in the clinical application of ferroptosis anticancer therapy, primarily due to the poor efficiency of intracellular Fenton reaction. To address this issue, we developed a supramolecular self-assembled codelivery nanoprodrug (DOX@C18Fc-Q[7] NPs) composed of ferrocene (Fc)-based supramolecular amphiphiles (C18Fc-Q[7]) and a nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) activator (doxorubicin, DOX). The C18Fc-Q[7] is based on Fc linked to a hydrophobic long-chain alkane via a disulfide linkage, which interacts with hydrophilic Q[7] to form self-assembled amphiphiles. Importantly, the host-guest interaction between Q[7] and Fc effectively enhances the solubility of Fc while maintaining the stability of the Fe<sup>2+</sup> source. Moreover, C18Fc-Q[7] also acts as a good carrier for loading DOX due to its good self-assembly. In cancer cells, elevated glutathione (GSH) triggers the disassembly of nanoprodrug, leading to the release of DOX, which upregulates NOX4 expression and increases H<sub>2</sub>O<sub>2</sub> level, thereby promoting an efficient Fenton reaction for Fc-induced ferroptosis. Moreover, DOX induces cell death through apoptosis, providing a synergistic effect to further enhance the ferroptosis therapy. <i>In vivo</i> studies have demonstrated that this enhanced ferroptosis therapy effectively inhibits tumor growth and metastasis while maintaining good biosafety.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guanqi Liu, Ruidi Xia, Mixiao Gui, Linjun Zhang, Xuan Zhou, Junlong Xue, Yihua Cai, Yang Cao, Yin Xiao, Zetao Chen
Mesoporous silica nanoparticles (MSNs) have gained wide application as excellent carrier materials; however, their limited degradation in the biological system and potential chronic toxicity pose challenges to their clinical applications. Previous studies have focused on optimizing the elimination performance of MSNs; interestingly, silicon has been well-documented as an essential body component. Therefore, converting MSNs into a form readily utilizable by the organism is a way to turn waste into a valuable resource. However, the recycling and utilization of MSNs are associated with significant hurdles. This study proposes an approach to impede the formation of siloxane, the crucial core in MSNs, by introducing a gradient concentration of Mg2+. The invasion of Mg2+ significantly reduces the stability of Si-O-Si bonds by substituting silicon ions while preserving the functional three-dimensional structure. Recycling the increased release of Mg and Si ions enhances cellular antioxidant capacity, reduces oxidative stress reactions, improves mitochondrial function, and regulates macrophage inflammatory states. The proposed approach to converting MSN materials shows significant advantages for tissue regeneration in the periodontal defect model. This study opens an insight for applying MSNs in clinical applications in regenerative medicine.
{"title":"Turn Hood into Good: Recycling Silicon from Mesoporous Silica Nanoparticles through Magnesium Modification to Lower Toxicity and Promote Tissue Regeneration.","authors":"Guanqi Liu, Ruidi Xia, Mixiao Gui, Linjun Zhang, Xuan Zhou, Junlong Xue, Yihua Cai, Yang Cao, Yin Xiao, Zetao Chen","doi":"10.1021/acsnano.4c12519","DOIUrl":"https://doi.org/10.1021/acsnano.4c12519","url":null,"abstract":"<p><p>Mesoporous silica nanoparticles (MSNs) have gained wide application as excellent carrier materials; however, their limited degradation in the biological system and potential chronic toxicity pose challenges to their clinical applications. Previous studies have focused on optimizing the elimination performance of MSNs; interestingly, silicon has been well-documented as an essential body component. Therefore, converting MSNs into a form readily utilizable by the organism is a way to turn waste into a valuable resource. However, the recycling and utilization of MSNs are associated with significant hurdles. This study proposes an approach to impede the formation of siloxane, the crucial core in MSNs, by introducing a gradient concentration of Mg<sup>2+</sup>. The invasion of Mg<sup>2+</sup> significantly reduces the stability of Si-O-Si bonds by substituting silicon ions while preserving the functional three-dimensional structure. Recycling the increased release of Mg and Si ions enhances cellular antioxidant capacity, reduces oxidative stress reactions, improves mitochondrial function, and regulates macrophage inflammatory states. The proposed approach to converting MSN materials shows significant advantages for tissue regeneration in the periodontal defect model. This study opens an insight for applying MSNs in clinical applications in regenerative medicine.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14DOI: 10.1182/blood.2023023287
Shuyan Yao, Lingbo He, Dina Suolitiken, Heshan Zou, Yingxin Zhu, Yini Wang
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by aberrant immunological activity with a dismal prognosis. Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) is the most common type among adults. Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer cells, or multilineages. The necessity of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with EBV-HLH remains controversial. A total of 356 adult patients with EBV-HLH entered this study. Eighty-eight received HSCT under medical recommendation. Four received salvage HSCT. The 5-year overall survival (OS) rate for patients who underwent HSCT was 48.7% (vs 16.2% in patients who did not undergo transplantation; P < .001). There was no difference in OS between patients who received transplantation at first complete response (CR1) and those at first partial response (PR1) nor between patients at CR1 and CR2. Patients who received transplantation at PR2 had inferior survival. The rate of reaching CR2 was significantly higher in patients with CR1 than PR1 (P = .014). Higher soluble CD25 levels, higher EBV-DNA loads in plasma after HSCT, poorer remission status, more advanced acute graft-versus-host disease (GVHD), and the absence of localized chronic GVHD were associated with inferior prognosis (P < .05). HSCT improved the survival of adult EBV-HLH significantly. For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment but with the risk of failing to achieve CR2.
{"title":"Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?","authors":"Shuyan Yao, Lingbo He, Dina Suolitiken, Heshan Zou, Yingxin Zhu, Yini Wang","doi":"10.1182/blood.2023023287","DOIUrl":"10.1182/blood.2023023287","url":null,"abstract":"<p><strong>Abstract: </strong>Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by aberrant immunological activity with a dismal prognosis. Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) is the most common type among adults. Patients with EBV infection to B cells could benefit from rituximab, whereas lethal outcomes may occur in patients with EBV infection to T cells, nature killer cells, or multilineages. The necessity of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with EBV-HLH remains controversial. A total of 356 adult patients with EBV-HLH entered this study. Eighty-eight received HSCT under medical recommendation. Four received salvage HSCT. The 5-year overall survival (OS) rate for patients who underwent HSCT was 48.7% (vs 16.2% in patients who did not undergo transplantation; P < .001). There was no difference in OS between patients who received transplantation at first complete response (CR1) and those at first partial response (PR1) nor between patients at CR1 and CR2. Patients who received transplantation at PR2 had inferior survival. The rate of reaching CR2 was significantly higher in patients with CR1 than PR1 (P = .014). Higher soluble CD25 levels, higher EBV-DNA loads in plasma after HSCT, poorer remission status, more advanced acute graft-versus-host disease (GVHD), and the absence of localized chronic GVHD were associated with inferior prognosis (P < .05). HSCT improved the survival of adult EBV-HLH significantly. For patients who achieved PR after initial treatment, HSCT was recommended. A wait-and-see strategy could be adopted for patients who achieved CR after initial treatment but with the risk of failing to achieve CR2.</p>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":" ","pages":"2107-2120"},"PeriodicalIF":21.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-11DOI: 10.1016/j.jacc.2024.08.078
Jeremy P. Moore, Kalyanam Shivkumar
Section snippets
Funding Support and Author Disclosures
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
章节片段资金支持和作者披露作者报告称,他们没有与本文内容相关的关系需要披露。
{"title":"The Rebirth of Intraoperative Electrophysiological Mapping for Complex Congenital Heart Disease","authors":"Jeremy P. Moore, Kalyanam Shivkumar","doi":"10.1016/j.jacc.2024.08.078","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.08.078","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Funding Support and Author Disclosures</h2>The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</section></section>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":"95 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-11DOI: 10.1016/j.jacc.2024.10.066
Kalyanam Shivkumar, Harlan M. Krumholz
Section snippets
Serving the Cardiovascular Community: The Power of Integration
Our goal is simple but transformative: to better serve the cardiovascular community by delivering the highest-quality content in a more integrated and efficient manner. Readers care more about the science than the specific journal in which it appears. By coordinating our efforts across JACC and JACC: Clinical Electrophysiology, we can ensure that important research reaches the right audience faster, with less redundancy and more cohesion.This approach allows us to maintain each journal's
A Commitment to Innovation and Impact
This new approach is not just about operational efficiency—it is about maximizing the impact of the work we publish. By working together, JACC and JACC: Clinical Electrophysiology can take a broader, more comprehensive view of cardiovascular research, identifying the studies with the greatest potential to transform care. The combined editorial expertise enables us to provide more rigorous peer reviews, better-informed evaluations, and faster decisions—all of which contribute to elevating the
Building a "Team of Teams": Our Shared Vision for the Future
At the core of this initiative is a shared vision for the future of cardiovascular publishing. As famed UCLA Coach John Wooden wisely said, “The star of the team is the team.” Our goal is to create a “team of teams,” where the collective expertise and dedication of our editors, reviewers, authors, and publishing staff work in unison to create something greater than the sum of its parts. This spirit of teamwork will guide us as we refine and expand this integration model, with plans to extend
{"title":"A Bold New Era of Collaboration: JACC and JACC Clinical Electrophysiology Unite","authors":"Kalyanam Shivkumar, Harlan M. Krumholz","doi":"10.1016/j.jacc.2024.10.066","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.066","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Serving the Cardiovascular Community: The Power of Integration</h2>Our goal is simple but transformative: to better serve the cardiovascular community by delivering the highest-quality content in a more integrated and efficient manner. Readers care more about the science than the specific journal in which it appears. By coordinating our efforts across <em>JACC</em> and <em>JACC: Clinical Electrophysiology</em>, we can ensure that important research reaches the right audience faster, with less redundancy and more cohesion.This approach allows us to maintain each journal's</section></section><section><section><h2>A Commitment to Innovation and Impact</h2>This new approach is not just about operational efficiency—it is about maximizing the impact of the work we publish. By working together, <em>JACC</em> and <em>JACC: Clinical Electrophysiology</em> can take a broader, more comprehensive view of cardiovascular research, identifying the studies with the greatest potential to transform care. The combined editorial expertise enables us to provide more rigorous peer reviews, better-informed evaluations, and faster decisions—all of which contribute to elevating the</section></section><section><section><h2>Building a \"Team of Teams\": Our Shared Vision for the Future</h2>At the core of this initiative is a shared vision for the future of cardiovascular publishing. As famed UCLA Coach John Wooden wisely said, “The star of the team is the team.” Our goal is to create a “team of teams,” where the collective expertise and dedication of our editors, reviewers, authors, and publishing staff work in unison to create something greater than the sum of its parts. This spirit of teamwork will guide us as we refine and expand this integration model, with plans to extend</section></section>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":"24 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-11DOI: 10.1016/j.jacc.2024.10.063
Cathleen Biga, Geoffrey A. Rose
Section snippets
The Landscape of Cardiovascular Employment Models
There are roughly 6 distinct types of employment models in today’s cardiovascular practice landscape, spanning from the more traditional models of independent practice and academic medicine to newer integrated health system models and private equity-backed ventures.
Recognizing Nonclinical Competencies in Clinical Practice
Regardless of the chosen employment model, effective organizational management and leadership are essential to ensuring excellence in patient care, clinician satisfaction, and long-term financial viability. Independent practices have long recognized this by integrating clinicians into these nonclinical roles. Typically, lead clinicians in these practices take on key managerial and executive roles (often in a dyad relationship), ensuring that daily operations are run efficiently, and the right
A Way Forward
Health systems and corporate entities must recognize and reward the nonclinical work of physicians. Clinician insight is invaluable when shaping care delivery models, and failure to acknowledge this input not only undervalues the clinician's contribution but also imperils the quality of care. Compensation structures must account for the opportunity cost of nonclinical work, acknowledging that time spent on administrative or leadership duties is time taken away from direct patient care.Various
{"title":"Navigating Cardiovascular Employment Trends","authors":"Cathleen Biga, Geoffrey A. Rose","doi":"10.1016/j.jacc.2024.10.063","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.063","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>The Landscape of Cardiovascular Employment Models</h2>There are roughly 6 distinct types of employment models in today’s cardiovascular practice landscape, spanning from the more traditional models of independent practice and academic medicine to newer integrated health system models and private equity-backed ventures.</section></section><section><section><h2>Recognizing Nonclinical Competencies in Clinical Practice</h2>Regardless of the chosen employment model, effective organizational management and leadership are essential to ensuring excellence in patient care, clinician satisfaction, and long-term financial viability. Independent practices have long recognized this by integrating clinicians into these nonclinical roles. Typically, lead clinicians in these practices take on key managerial and executive roles (often in a dyad relationship), ensuring that daily operations are run efficiently, and the right</section></section><section><section><h2>A Way Forward</h2>Health systems and corporate entities must recognize and reward the nonclinical work of physicians. Clinician insight is invaluable when shaping care delivery models, and failure to acknowledge this input not only undervalues the clinician's contribution but also imperils the quality of care. Compensation structures must account for the opportunity cost of nonclinical work, acknowledging that time spent on administrative or leadership duties is time taken away from direct patient care.Various</section></section>","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":"14 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}